In the case of SMR and HF, the treatment of choice includes beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRA), which can partially attenuate LV dilatation and remodeling after myocardial injury. Here, ACE is linked to hydrops fetalis.